Effect of granulocyte colony-stimulating factor on neutropenia in liver transplant recipients with hypersplenism.

Abstract

The authors present details of their initial experience with use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) for preventing neutropenia caused by hypersplenism, and, possibly, for reducing the risk of postoperative infections in pediatric liver transplant recipients. Seven patients with end-stage liver disease, three of whom had severe hypersplenism, underwent living related liver transplantation (LRLT). The rhG-CSF was administered to the latter three patients. Peripheral neutrophil counts decreased immediately after reperfusion (to 1500 +/- 300/microL) in the three patients, and returned to normal with use of rhG-CSF 3 to 10 days after transplantation. The dosage was adjusted to maintain peripheral leukocyte and granulocyte counts above 5,000/microL and 2,000/microL, respectively. This initial clinical trial showed that rhG-CSF administration restores the leukocyte counts of patients who have hypersplenism, without any significant adverse effects, and that rhG-CSF holds promise for reducing the risk of infections after liver transplantation.

• Authors: S Ishizone, M Makuuchi, S Kawasaki, H Matsunami, M Terada, S Kitahara, N Kamada, T Nakahata, H Kawarasaki, T Iwanaka
• Journal: Journal of pediatric surgery (J Pediatr Surg) Vol. 29 Issue 4 Pg. 510-3 (Apr 1994) ISSN: 0022-3468 [Print] United States
• PMID: 7516966 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Recombinant Proteins
• Granulocyte Colony-Stimulating Factor

Topics

• Child
• Female
• Granulocyte Colony-Stimulating Factor (therapeutic use)
• Humans
• Hypersplenism (complications)
• Infant
• Leukocyte Count
• Liver Diseases (surgery)
• Liver Transplantation
• Male
• Neutropenia (blood, etiology, therapy)
• Recombinant Proteins (therapeutic use)